22 results on '"Mary Vu"'
Search Results
2. Supplementary Table 2 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- Author
-
Eric A. Collisson, AmirAli Talasaz, Pamela N. Munster, Trever G. Bivona, Margaret A. Tempero, Andrew H. Ko, Katherine Van Loon, Robin K. Kelley, Chloe E. Atreya, Zhen Wang, Andrew E. Hendifar, Mary Vu, Jim Leng, Lai Mun Siew, Dragan Sebisanovic, Claire Greene, and Oliver A. Zill
- Abstract
Complete patient-level and mutation-level concordance information, mutation identities, and monitoring status for each patient in study.
- Published
- 2023
3. Supplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- Author
-
Eric A. Collisson, AmirAli Talasaz, Pamela N. Munster, Trever G. Bivona, Margaret A. Tempero, Andrew H. Ko, Katherine Van Loon, Robin K. Kelley, Chloe E. Atreya, Zhen Wang, Andrew E. Hendifar, Mary Vu, Jim Leng, Lai Mun Siew, Dragan Sebisanovic, Claire Greene, and Oliver A. Zill
- Abstract
Comparisons of CA 19-9 concentration and cfDNA mutant allele fractions in plasma. (A-E) cfDNA mutant allele fractions ("cfDNA percentage") versus CA 19-9 units per milliliter (U/mL) were determined at similar times for five patients with three or more serial blood draws. cfDNA percentage represents the mutant allele fraction of the most abundant cfDNA mutation, as determined at time zero, for each patient. (F) cfDNA mutant allele fractions and CA 19-9 marker measurements for patient 56 over the course of four time points while on therapy (gemcitabine nab-paclitaxel). Note that draw number 1 occurred 17 days after diagnosis.
- Published
- 2023
4. Supplementary Table 4 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- Author
-
Eric A. Collisson, AmirAli Talasaz, Pamela N. Munster, Trever G. Bivona, Margaret A. Tempero, Andrew H. Ko, Katherine Van Loon, Robin K. Kelley, Chloe E. Atreya, Zhen Wang, Andrew E. Hendifar, Mary Vu, Jim Leng, Lai Mun Siew, Dragan Sebisanovic, Claire Greene, and Oliver A. Zill
- Abstract
List of genes and exons captured in the Guardant360 cfDNA sequencing test.
- Published
- 2023
5. Supplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- Author
-
Eric A. Collisson, AmirAli Talasaz, Pamela N. Munster, Trever G. Bivona, Margaret A. Tempero, Andrew H. Ko, Katherine Van Loon, Robin K. Kelley, Chloe E. Atreya, Zhen Wang, Andrew E. Hendifar, Mary Vu, Jim Leng, Lai Mun Siew, Dragan Sebisanovic, Claire Greene, and Oliver A. Zill
- Abstract
Characteristics of the 26 patients in study.
- Published
- 2023
6. Data from Transforming Growth Factor-β Can Suppress Tumorigenesis through Effects on the Putative Cancer Stem or Early Progenitor Cell and Committed Progeny in a Breast Cancer Xenograft Model
- Author
-
Lalage M. Wakefield, W. Tony Parks, Joanna Shih, Aleksandra M. Michalowska, Miriam R. Anver, Pierre-Yves Desprez, Zhijun Du, Akira Ooshima, Jeong-Seok Nam, Mizuko Mamura, Mary Vu, Naomi Yoo, and Binwu Tang
- Abstract
The transforming growth factor-β (TGF-β) pathway has tumor-suppressor activity in many epithelial tissues. Because TGF-β is a potent inhibitor of epithelial cell proliferation, it has been widely assumed that this property underlies the tumor-suppressor effect. Here, we have used a xenograft model of breast cancer to show that endogenous TGF-β has the potential to suppress tumorigenesis through a novel mechanism, involving effects at two distinct levels in the hierarchy of cellular progeny that make up the epithelial component of the tumor. First, TGF-β reduces the size of the putative cancer stem or early progenitor cell population, and second it promotes differentiation of a more committed, but highly proliferative, progenitor cell population to an intrinsically less proliferative state. We further show that reduced expression of the type II TGF-β receptor correlates with loss of luminal differentiation in a clinical breast cancer cohort, suggesting that this mechanism may be clinically relevant. At a molecular level, the induction of differentiation by TGF-β involves down-regulation of Id1, and forced overexpression of Id1 can promote tumorigenesis despite persistence of the antiproliferative effect of TGF-β. These data suggest new roles for the TGF-β pathway in regulating tumor cell dynamics that are independent of direct effects on proliferation. [Cancer Res 2007;67(18):8643–52]
- Published
- 2023
7. Supplementary Figures 1-5 from Transforming Growth Factor-β Can Suppress Tumorigenesis through Effects on the Putative Cancer Stem or Early Progenitor Cell and Committed Progeny in a Breast Cancer Xenograft Model
- Author
-
Lalage M. Wakefield, W. Tony Parks, Joanna Shih, Aleksandra M. Michalowska, Miriam R. Anver, Pierre-Yves Desprez, Zhijun Du, Akira Ooshima, Jeong-Seok Nam, Mizuko Mamura, Mary Vu, Naomi Yoo, and Binwu Tang
- Abstract
Supplementary Figures 1-5 from Transforming Growth Factor-β Can Suppress Tumorigenesis through Effects on the Putative Cancer Stem or Early Progenitor Cell and Committed Progeny in a Breast Cancer Xenograft Model
- Published
- 2023
8. Supplementary Table 1 from Transforming Growth Factor-β Can Suppress Tumorigenesis through Effects on the Putative Cancer Stem or Early Progenitor Cell and Committed Progeny in a Breast Cancer Xenograft Model
- Author
-
Lalage M. Wakefield, W. Tony Parks, Joanna Shih, Aleksandra M. Michalowska, Miriam R. Anver, Pierre-Yves Desprez, Zhijun Du, Akira Ooshima, Jeong-Seok Nam, Mizuko Mamura, Mary Vu, Naomi Yoo, and Binwu Tang
- Abstract
Supplementary Table 1 from Transforming Growth Factor-β Can Suppress Tumorigenesis through Effects on the Putative Cancer Stem or Early Progenitor Cell and Committed Progeny in a Breast Cancer Xenograft Model
- Published
- 2023
9. Large area chemical vapor deposition growth of monolayer MoSe2 and its controlled sulfurization to MoS2
- Author
-
Deji Akinwande, Mary Vu, Anupam Roy, Joon-Seok Kim, Rudresh Ghosh, Harry Chou, and Sanjay K. Banerjee
- Subjects
Materials science ,Inorganic chemistry ,chemistry.chemical_element ,Nanotechnology ,02 engineering and technology ,Chemical vapor deposition ,010402 general chemistry ,01 natural sciences ,chemistry.chemical_compound ,symbols.namesake ,Transition metal ,Selenide ,Monolayer ,General Materials Science ,Hybrid physical-chemical vapor deposition ,Mechanical Engineering ,Combustion chemical vapor deposition ,021001 nanoscience & nanotechnology ,Condensed Matter Physics ,0104 chemical sciences ,chemistry ,Mechanics of Materials ,Molybdenum ,symbols ,0210 nano-technology ,Raman spectroscopy - Abstract
Layered transition metal dichalcogenides which are part of the two dimensional materials family are experiencing rapidly growing interest owing to their diverse physical and optoelectronic properties. Large area controllable synthesis of these materials is required for transition from lab scale research to practical applications. In this work, we present a single step chemical vapor deposition process for large area monolayer growth of molybdenum selenide (MoSe2). We also demonstrate controllable thermal conversion from molybdenum selenide to molybdenum sulfide.
- Published
- 2016
10. A comprehensive profile of the sociodemographic, psychosocial and health characteristics of Ontario home care clients with dementia
- Author
-
Nathalie Jette, Marie-Jeanne Kergoat, Scott B. Patten, Colleen J. Maxwell, Susan E. Bronskill, X. Chen, Mary Vu, John P. Hirdes, George A. Heckman, David B. Hogan, and M. M. Zehr
- Subjects
medicine.medical_specialty ,Epidemiology ,business.industry ,Public Health, Environmental and Occupational Health ,General Medicine ,medicine.disease ,Mental health ,Cohort ,Medicine ,Anxiety ,Dementia ,Alzheimer's disease ,medicine.symptom ,business ,Psychiatry ,Psychosocial ,Depression (differential diagnoses) ,Cohort study - Abstract
Introduction This study provides a comprehensive summary of the sociodemographic, psychosocial and health characteristics of a large population-based cohort of Ontario home care clients (aged 50 years and over) with dementia and examines the variation in these characteristics in those with co-existing neurological conditions. Methods Clients were assessed with the Resident Assessment Instrument-Home Care (RAI-HC) between January 2003 and December 2010. Descriptive analyses examined the distribution of these characteristics among clients with dementia relative to several comparison groups, as well as clients with other recorded neurological conditions. Results Approximately 22% of clients (n = 104 802) had a diagnosis of dementia (average age 83 years, 64% female) and about one in four within this group had a co-existing neurological condition (most commonly stroke or Parkinson disease). About 43% of those with dementia did not live with their primary caregiver. Relative to several comparison groups, clients with dementia showed considerably higher levels of cognitive and functional impairment, aggression, anxiety, wandering, hallucinations/delusions, caregiver distress and a greater risk for institutionalization. Conversely, they showed a lower prevalence of several chronic conditions and lower levels of recent health service use. Depressive symptoms were relatively common in the dementia and other neurological groups. Conclusion Clients with co-existing neurological conditions exhibited unique clinical profiles illustrating the need for tailored and flexible home care services and enhanced caregiver assistance programs.
- Published
- 2014
11. Profil complet des caractéristiques sociodémographiques, psychosociales et sanitaires des clients des soins à domicile atteints de démence en Ontario
- Author
-
Scott B. Patten, Colleen J. Maxwell, X. Chen, Nathalie Jette, Mary Vu, Susan E. Bronskill, George A. Heckman, M. M. Zehr, Marie-Jeanne Kergoat, John P. Hirdes, and David B. Hogan
- Abstract
Introduction Cette étude fournit une synthèse des caractéristiques sociodémographiques, psychosociales et sanitaires d'une vaste cohorte représentative des clients des soins à domicile en Ontario (âgés de 50 ans ou plus) atteints de démence et elle examine les variations de ces caractéristiques chez les clients atteints de maladies neurologiques concomitantes. Méthodologie Les clients ont été évalués à l'aide de l'Instrument d'évaluation des résidents – Soins à domicile (RAI-HC) entre janvier 2003 et décembre 2010. Les analyses descriptives fournissent la répartition de ces caractéristiques en comparant les clients atteints de démence et ceux de plusieurs autres groupes ainsi que ceux atteints d'autres maladies neurologiques documentées. Résultats Environ 22 % des clients (n = 104 802) avaient reçu un diagnostic de démence (âge moyen de 83 ans, 64 % de femmes) et un sur quatre parmi eux était atteint d'une maladie neurologique concomitante (AVC ou maladie de Parkinson la plupart du temps). Environ 43 % des clients atteints de démence n'habitaient pas avec leur principal aidant. Par rapport aux clients des groupes de comparaison, les clients atteints de démence présentaient des taux considérablement plus élevés de déficit cognitif et fonctionnel, d'agressivité, d'anxiété, d'errance et d'hallucinations ou de délire, avaient plus souvent un aidant en détresse et couraient un plus grand risque de placement en établissement. Par contre, ils étaient moins souvent atteints de diverses maladies chroniques et étaient moins nombreux à avoir eu recours à des services de santé récemment. Les symptômes de dépression étaient relativement fréquents chez les clients atteints de démence et chez ceux atteints d'une autre maladie neurologique. Conclusion Les clients atteints de maladies neurologiques concomitantes présentaient des profils cliniques bien particuliers illustrant la nécessité de personnaliser et d'assouplir les services de soins à domicile et d'améliorer les programmes de soutien pour les aidants.
- Published
- 2014
12. New allergies after cord blood transplantation
- Author
-
Madan Jagasia, Brian G. Engelhardt, Adetola A. Kassim, Stacey Goodman, Carey Clifton, Karen Mccarty, David Hagaman, C. Lucid, Jennifer Domm, Leigh Ann Vaughan, John P. Greer, Haydar Frangoul, Mary Vu, Salyka Sengsayadeth, Wichai Chinratanalab, and Bipin N. Savani
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Allergy ,Pediatrics ,Time Factors ,Adolescent ,Immunology ,behavioral disciplines and activities ,Young Adult ,Postoperative Complications ,Hypersensitivity ,Humans ,Immunology and Allergy ,Medicine ,Effective treatment ,Cumulative incidence ,Prospective Studies ,Child ,Genetics (clinical) ,Cord blood transplantation ,Transplantation ,business.industry ,Umbilical Cord Blood Transplantation ,Incidence ,Infant ,Cell Biology ,Middle Aged ,medicine.disease ,Survival Analysis ,Confidence interval ,Surgery ,Oncology ,Child, Preschool ,Hematologic Neoplasms ,Female ,Cord Blood Stem Cell Transplantation ,business ,Complication ,Follow-Up Studies - Abstract
Background aims Umbilical cord blood transplantation (CBT) is an effective treatment for benign and malignant diseases. Late effects of CBT are not well described in the literature. In the present study, we present our experience of new-onset allergies in long-term survivors after CBT. Methods After an initial patient had a severe peanut allergic reaction after CBT, all CBT patients were prospectively followed for new allergy development. Fifty patients received CBT between March 2006 and June 2011. Results The median follow-up after CBT was 447 days (range, 12–2022). At the time of analysis, 30 patients were alive, with 3-year survival of 55.5%; median follow-up of surviving patients was 910 days (range, 68–2022). The allergic syndrome developed in five patients, with the cumulative incidence of new allergies at 2 years of 18.4% (95% confidence interval, 10.8–26). The median time to onset of new allergy after transplantation was 298 days (range, 250–809). Conclusions Allergy development has been linked to a delayed maturation of the immune system in several studies. We present the first case series of patients who had new allergies after CBT. Further study of this novel complication as well as counseling of patients after CBT would be important.
- Published
- 2013
13. Examining correlates of different cigarette access behaviours among Canadian youth: Data from the Canadian Youth Smoking Survey (2006)
- Author
-
Scott T. Leatherdale, Rashid Ahmed, and Mary Vu
- Subjects
Male ,Canada ,Health Knowledge, Attitudes, Practice ,Future studies ,education ,Medicine (miscellaneous) ,Binge drinking ,Youth smoking ,Toxicology ,Odds ,Social Facilitation ,Risk Factors ,Environmental health ,Tobacco ,Humans ,Students ,Health policy ,Schools ,Smoking ,Commerce ,Purchasing ,Psychiatry and Mental health ,Clinical Psychology ,Cross-Sectional Studies ,Female ,Self Report ,Psychology - Abstract
Understanding factors associated with youth cigarette access behaviours can provide insight into the development of more effective means of preventing youth from accessing cigarettes. This cross-sectional study used self-reported data collected from 41,886 students in grades 9 to 12 who participated in the 2006–07 Youth Smoking Survey to examine the student- and school-level characteristics that differentiate youth smokers who usually access cigarettes from a social source versus buying their own from retailers. Multi-level regression analyses revealed significant between-school variability in the odds of a smoking student reporting that they usually buy their own cigarettes. Important student-level characteristics associated with how youth usually access their cigarettes included binge drinking and being asked for age or photo identification when purchasing cigarettes from a retailer. Future studies should further explore the school- and student-level characteristics associated with youth cigarette access behaviour.
- Published
- 2011
14. Factors Associated with Different Cigarette Access Behaviours Among Underage Smoking Youth Who Usually Smoke Contraband (Native) Cigarettes
- Author
-
Scott T, Leatherdale, Rashid, Ahmed, and Mary, Vu
- Subjects
Male ,Canada ,Adolescent ,Smoking ,Commerce ,Public Health, Environmental and Occupational Health ,Tobacco Industry ,General Medicine ,Peer Group ,Adolescent Behavior ,Humans ,Family ,Female ,Quantitative Research - Abstract
Objectives: Given that little is known about how youth access contraband cigarettes, the current study seeks to examine factors associated with how underage smoking youth report usually accessing contraband cigarettes. Methods: This study used nationally representative data collected from 41,886 students (grades 9 to 12) as part of the 2006–07 Canadian Youth Smoking Survey (YSS). Using data from current smokers who report that their usual brand of cigarettes is contraband, three logistic regression models were used to examine factors associated with buying cigarettes from a store, getting cigarettes from a family member, or getting cigarettes from friends or strangers. Results: In 2006, 7.9% (n=13,300) of Canadian youth who were current smokers reported that their usual brand of cigarettes was contraband. Among these youth, the majority reported that they usually get their cigarettes from a friend or stranger (54.8%), whereas 26.4% report usually getting them from a family member and 18.8% usually buying their own from a store. Boys were more likely to buy contraband cigarettes from a store, whereas youth with a parent who smokes contraband cigarettes were substantially more likely to get contraband cigarettes from a family member and youth with friends who smoke contraband cigarettes were substantially more likely to get contraband cigarettes from a friend or stranger. Conclusion: Ongoing surveillance of contraband cigarette use among youth and how youth access contraband cigarettes is required for guiding future tobacco control policy and programming activities.
- Published
- 2011
15. Inscribing the Perimeter of the PagP Hydrocarbon Ruler by Site-Specific Chemical Alkylation
- Author
-
Thomas Pinter, Russell E. Bishop, Patrick J. Mott, Mary Vu, Fraser Hof, Joel Moktar, Aaron H. McKie, and M. Adil Khan
- Subjects
Models, Molecular ,Spectrometry, Mass, Electrospray Ionization ,Alkylation ,Protein Conformation ,Stereochemistry ,Phospholipid ,Peptide ,Biochemistry ,Article ,Lipid A ,chemistry.chemical_compound ,Protein structure ,Palmitoylation ,Escherichia coli ,Nuclear Magnetic Resonance, Biomolecular ,DNA Primers ,chemistry.chemical_classification ,Binding Sites ,Base Sequence ,Protein Stability ,Chemistry ,Circular Dichroism ,Escherichia coli Proteins ,Recombinant Proteins ,Amino Acid Substitution ,Acyltransferases ,Mutagenesis, Site-Directed ,Mutant Proteins ,lipids (amino acids, peptides, and proteins) ,Bacterial outer membrane ,Bacterial Outer Membrane Proteins - Abstract
The Escherichia coli outer membrane phospholipid:lipid A palmitoyltransferase PagP selects palmitate chains using its β-barrel-interior hydrocarbon ruler and interrogates phospholipid donors by gating them laterally through an aperture known as the crenel. Lipid A palmitoylation provides antimicrobial peptide resistance and modulates inflammation signaled through the host TLR4/MD2 pathway. Gly88 substitutions can raise the PagP hydrocarbon ruler floor to correspondingly shorten the selected acyl chain. To explore the limits of hydrocarbon ruler acyl chain selectivity, we have modified the single Gly88Cys sulfhydryl group with linear alkyl units and identified C10 as the shortest acyl chain to be efficiently utilized. Gly88Cys-S-ethyl, S-n-propyl, and S-n-butyl PagP were all highly specific for C12, C11, and C10 acyl chains, respectively, and longer aliphatic or aminoalkyl substitutions could not extend acyl chain selectivity any further. The donor chain length limit of C10 coincides with the phosphatidylcholine transition from displaying bilayer to micellar properties in water, but the detergent inhibitor lauryldimethylamine N-oxide also gradually became ineffective in a micellar assay as the selected acyl chains were shortened to C10. The Gly88Cys-S-ethyl and norleucine substitutions exhibited superior C12 acyl chain specificity compared to that of Gly88Met PagP, thus revealing detection by the hydrocarbon ruler of the Met side chain tolerance for terminal methyl group gauche conformers. Although norleucine substitution was benign, selenomethionine substitution at Met72 was highly destabilizing to PagP. Within the hydrophobic and van der Waals-contacted environment of the PagP hydrocarbon ruler, side chain flexibility, combined with localized thioether-aromatic dispersion attraction, likely influences the specificity of acyl chain selection.
- Published
- 2010
16. Transforming Growth Factor-β Can Suppress Tumorigenesis through Effects on the Putative Cancer Stem or Early Progenitor Cell and Committed Progeny in a Breast Cancer Xenograft Model
- Author
-
Akira Ooshima, Lalage M. Wakefield, Jeong Seok Nam, Joanna Shih, Zhijun Du, Mizuko Mamura, Mary Vu, Aleksandra M. Michalowska, Pierre Yves Desprez, Naomi Yoo, W. Tony Parks, Miriam R. Anver, and Binwu Tang
- Subjects
Inhibitor of Differentiation Protein 1 ,Cancer Research ,Cellular differentiation ,Transplantation, Heterologous ,Population ,Down-Regulation ,Mice, Nude ,Breast Neoplasms ,Protein Serine-Threonine Kinases ,medicine.disease_cause ,Article ,Mice ,Transforming Growth Factor beta ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Progenitor cell ,education ,education.field_of_study ,biology ,Gene Expression Profiling ,Receptor, Transforming Growth Factor-beta Type II ,Cancer ,Cell Differentiation ,Transforming growth factor beta ,Endoglin ,medicine.disease ,Oncology ,Immunology ,Neoplastic Stem Cells ,biology.protein ,Cancer research ,Female ,Stem cell ,Carcinogenesis ,Receptors, Transforming Growth Factor beta ,Neoplasm Transplantation - Abstract
The transforming growth factor-β (TGF-β) pathway has tumor-suppressor activity in many epithelial tissues. Because TGF-β is a potent inhibitor of epithelial cell proliferation, it has been widely assumed that this property underlies the tumor-suppressor effect. Here, we have used a xenograft model of breast cancer to show that endogenous TGF-β has the potential to suppress tumorigenesis through a novel mechanism, involving effects at two distinct levels in the hierarchy of cellular progeny that make up the epithelial component of the tumor. First, TGF-β reduces the size of the putative cancer stem or early progenitor cell population, and second it promotes differentiation of a more committed, but highly proliferative, progenitor cell population to an intrinsically less proliferative state. We further show that reduced expression of the type II TGF-β receptor correlates with loss of luminal differentiation in a clinical breast cancer cohort, suggesting that this mechanism may be clinically relevant. At a molecular level, the induction of differentiation by TGF-β involves down-regulation of Id1, and forced overexpression of Id1 can promote tumorigenesis despite persistence of the antiproliferative effect of TGF-β. These data suggest new roles for the TGF-β pathway in regulating tumor cell dynamics that are independent of direct effects on proliferation. [Cancer Res 2007;67(18):8643–52]
- Published
- 2007
17. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- Author
-
Robin Kate Kelley, AmirAli Talasaz, Dragan Sebisanovic, Pamela N. Munster, Oliver A. Zill, Andrew H. Ko, Andrew Eugene Hendifar, Zhen Wang, Mary Vu, Lai Mun Siew, Margaret A. Tempero, Jim Leng, Katherine Van Loon, Eric A. Collisson, Trever G. Bivona, Chloe E. Atreya, and Claire Greene
- Subjects
Oncology ,medicine.medical_specialty ,Oncology and Carcinogenesis ,Biology ,Bioinformatics ,Sensitivity and Specificity ,DNA sequencing ,Article ,Pancreatic Cancer ,Rare Diseases ,Mutation Rate ,Internal medicine ,Genotype ,Carcinoma ,medicine ,Genetics ,Biomarkers, Tumor ,Humans ,Tumor marker ,Cancer ,Neoplasm Staging ,Tumor ,Gene Expression Profiling ,Human Genome ,High-Throughput Nucleotide Sequencing ,Reproducibility of Results ,DNA ,DNA, Neoplasm ,medicine.disease ,Precision medicine ,Prognosis ,Gene expression profiling ,Pancreatic Neoplasms ,Good Health and Well Being ,Cell-free fetal DNA ,Bile Duct Neoplasms ,Mutation ,Disease Progression ,Neoplasm ,Digestive Diseases ,Biomarkers - Abstract
Patients with pancreatic and biliary carcinomas lack personalized treatment options, in part because biopsies are often inadequate for molecular characterization. Cell-free DNA (cfDNA) sequencing may enable a precision oncology approach in this setting. We attempted to prospectively analyze 54 genes in tumor and cfDNA for 26 patients. Tumor sequencing failed in 9 patients (35%). In the remaining 17, 90.3% (95% confidence interval, 73.1%–97.5%) of mutations detected in tumor biopsies were also detected in cfDNA. The diagnostic accuracy of cfDNA sequencing was 97.7%, with 92.3% average sensitivity and 100% specificity across five informative genes. Changes in cfDNA correlated well with tumor marker dynamics in serial sampling (r = 0.93). We demonstrate that cfDNA sequencing is feasible, accurate, and sensitive in identifying tumor-derived mutations without prior knowledge of tumor genotype or the abundance of circulating tumor DNA. cfDNA sequencing should be considered in pancreatobiliary cancer trials where tissue sampling is unsafe, infeasible, or otherwise unsuccessful. Significance: Precision medicine efforts in biliary and pancreatic cancers have been frustrated by difficulties in obtaining adequate tumor tissue for next-generation sequencing. cfDNA sequencing reliably and accurately detects tumor-derived mutations, paving the way for precision oncology approaches in these deadly diseases. Cancer Discov; 5(10); 1040–8. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 1005
- Published
- 2015
18. TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression
- Author
-
Binwu, Tang, Mary, Vu, Timberly, Booker, Steven J, Santner, Fred R, Miller, Miriam R, Anver, and Lalage M, Wakefield
- Subjects
Transplantation, Heterologous ,Mammary Neoplasms, Experimental ,Antineoplastic Agents ,General Medicine ,Article ,Mice ,Cell Transformation, Neoplastic ,Transforming Growth Factor beta ,Disease Progression ,Tumor Cells, Cultured ,Animals ,Humans ,Female ,Neoplasm Metastasis ,Receptors, Transforming Growth Factor beta ,Neoplasm Transplantation - Abstract
The TGF-beta signaling network plays a complex role in carcinogenesis because it has the potential to act as either a tumor suppressor or a pro-oncogenic pathway. Currently, it is not known whether TGF-beta can switch from tumor suppressor to pro-oncogenic factor during the course of carcinogenic progression in a single cell lineage with a defined initiating oncogenic event or whether the specific nature of the response is determined by cell type and molecular etiology. To address this question, we have introduced a dominant negative type II TGF-beta receptor into a series of genetically related human breast-derived cell lines representing different stages in the progression process. We show that decreased TGF-beta responsiveness alone cannot initiate tumorigenesis but that it can cooperate with an initiating oncogenic lesion to make a premalignant breast cell tumorigenic and a low-grade tumorigenic cell line histologically and proliferatively more aggressive. In a high-grade tumorigenic cell line, however, reduced TGF-beta responsiveness has no effect on primary tumorigenesis but significantly decreases metastasis. Our results demonstrate a causal role for loss of TGF-beta responsiveness in promoting breast cancer progression up to the stage of advanced, histologically aggressive, but nonmetastatic disease and suggest that at that point TGF-beta switches from tumor suppressor to prometastatic factor.
- Published
- 2003
19. P4–147: Neuropsychiatric symptoms in dementia: Variation by care setting and gender
- Author
-
George A. Heckman, David B. Hogan, Nathalie Jette, Meaghan Zehr, Scott B. Patten, Colleen J. Maxwell, Marie-Jeanne Kergoat, Oana Danila, John P. Hirdes, Susan E. Bronskill, and Mary Vu
- Subjects
medicine.medical_specialty ,Epidemiology ,business.industry ,Health Policy ,medicine.disease ,Care setting ,Psychiatry and Mental health ,Cellular and Molecular Neuroscience ,Variation (linguistics) ,Developmental Neuroscience ,medicine ,Dementia ,Neurology (clinical) ,Geriatrics and Gerontology ,business ,Psychiatry ,Clinical psychology - Published
- 2013
20. Patterns and determinants of dementia pharmacotherapy in a population-based cohort of home care clients
- Author
-
George A. Heckman, Marie-Jeanne Kergoat, Mary Vu, Micaela Jantzi, Nathalie Jette, Scott B. Patten, Colleen J. Maxwell, John P. Hirdes, Susan E. Bronskill, and David B. Hogan
- Subjects
Male ,medicine.medical_specialty ,Health Status ,Pharmacology toxicology ,Disease ,Population based cohort ,Pharmacotherapy ,Memantine ,medicine ,Galantamine ,Dementia ,Humans ,Pharmacology (medical) ,Quality of care ,Psychiatry ,Geriatric Assessment ,Aged ,Rivastigmine ,Aged, 80 and over ,business.industry ,Middle Aged ,medicine.disease ,Home Care Services ,Cross-Sectional Studies ,Case-Control Studies ,Female ,Cholinesterase Inhibitors ,Geriatrics and Gerontology ,business ,Cognition Disorders ,medicine.drug - Abstract
Little is known about the needs of older home care clients with dementia or their key quality of care issues, including their use of pharmacotherapy for Alzheimer's disease.The objectives of this study were to (1) describe the sociodemographic, psychosocial, and health characteristics of clients with dementia (relative to two control subgroups) from a population-based home care cohort; and, (2) determine the distribution and associated characteristics of cholinesterase inhibitor (ChEI) and/or memantine use among dementia clients overall and according to medication class, comorbid illness, and year of assessment.This cross-sectional study included all home care clients aged 50 years or older assessed with the Resident Assessment Instrument-Home Care (RAI-HC) in Ontario, Canada from January 2003 to December 2010. Multivariable logistic regression models were used to identify factors associated with receiving a dementia medication (a ChEI and/or memantine).There were 104,802 (21.5 %) clients with a diagnosis of dementia, 92,529 (18.9 %) cognitively impaired clients without a dementia diagnosis, and 290,929 (59.6 %) cognitively intact clients. Relative to the comparison groups, dementia clients were more likely to have reported conflicts with others, a distressed caregiver, greater levels of cognitive and functional impairment, and to exhibit wandering, aggressive behaviors, anxiety, hallucinations or delusions, and swallowing problems. Approximately half of dementia clients were taking a dementia medication, most commonly donepezil. Characteristics most strongly associated with use of ChEI monotherapy included age greater than 64 (especially 75-84), absence of economic barriers, availability of a primary caregiver, year of assessment, moderate to severe cognitive impairment, relative independence in function, health stability, no depressive symptoms or hallucinations/delusions, no recent hospitalization, use of at least 9 medications, the absence of chronic health and neurological conditions, and the use of an antipsychotic or antidepressant. For combination therapy, strong positive associations were observed for younger age, year of assessment, increasing cognitive impairment, presence of a primary caregiver, male sex, absence of economic barriers, use of at least 9 medications, and various indicators of positive health status (e.g., stability in health, absence of chronic health and neurological conditions, and no recent hospitalization). The percentage of clients receiving ChEIs increased with cognitive impairment scores but declined slightly at the highest level of impairment, whereas the percentage receiving memantine increased with cognitive impairment level. The number and percentage of dementia clients receiving any pharmacotherapy increased during the study interval.We observed a relatively high prevalence of dementia-specific pharmacotherapy among Ontario long-stay home care clients as well as significant variation in utilization patterns by select sociodemographic, functional, and clinical characteristics, and over time. While physicians generally followed recommended guidelines regarding appropriate dementia pharmacotherapy, continued efforts to monitor practice patterns are required among vulnerable older adults across care settings.
- Published
- 2013
21. Where Is the Storm Coming From: A Case of Thyroid Storm Secondary to Ipilimumab
- Author
-
Mary Vu, Brian Fouty, Christopher Caesar Williams, Faiza Ferdousy, and Benjamin Sherman
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Pediatrics ,business.industry ,Thyroid Crisis ,Storm ,Ipilimumab ,Critical Care and Intensive Care Medicine ,Endocrinology ,Internal medicine ,Thyroid storm ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Published
- 2016
22. Large area chemical vapor deposition growth of monolayer MoSe2 and its controlled sulfurization to MoS2.
- Author
-
Ghosh, Rudresh, Kim, Joon-Seok, Roy, Anupam, Harry Chou, Mary Vu, Banerjee, Sanjay K., and Akinwande, Deji
- Subjects
TWO-dimensional materials (Nanotechnology) ,CHEMICAL vapor deposition ,MOLYBDENUM sulfides ,MONOMOLECULAR films ,CHALCOGENIDES ,MOLYBDENUM selenides - Abstract
Layered transition metal dichalcogenides which are part of the two dimensional materials family are experiencing rapidly growing interest owing to their diverse physical and optoelectronic properties. Large area controllable synthesis of these materials is required for transition from lab scale research to practical applications. In this work, we present a single step chemical vapor deposition process for large area monolayer growth of molybdenum selenide (MoSe
2 ). We also demonstrate controllable thermal conversion from molybdenum selenide to molybdenum sulfide. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.